ArticleFundamental & clinical pharmacology2026
The Challenges of Scientific Publishing: An Editor-In-Chief's Perspective.
Article in Fundamental & clinical pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The Challenges of Scientific Publishing: An Editor-In-Chief's Perspective.Fundamental & clinical pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The current and former editors-in-chief of the Fundamental & Clinical Pharmacology journal share their experience and perspectives regarding the present landscape of scientific publishing and the challenges and threats it faces. Several challenges are identified, three of which are of particular significance. The first is how to manage the growing number of submissions. This is a global trend: The number of indexed articles has increased by 50% in less than 10 years, and the challenge of finding efficient and motivated reviewers is particularly acute. The second challenge is how the impact factor has come to be the sole quality criterion for a scientific journal, and by extension for evaluating researchers: Might there not be alternatives? The third challenge is publication fraud, where the editor-in-chief is invariably exposed to endless attempts at manipulation. However, there are fortunately now tools to help combat this. Of course, the editor-in-chief's ultimate weapon is the power to retract a suspicious article, but this is not so simple and is not without consequences.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.